RANKL-targeted therapy inhibits bone resorption in experimental Staphylococcus aureus-induced arthritis.

Verdrengh, Margareta; Bokarewa, Maria; Ohlsson, Claes; Stolina, Marina; Tarkowski, Andrej

Verdrengh, Margareta; Bokarewa, Maria; Ohlsson, Claes; Stolina, Marina; Tarkowski, Andrej.

Affiliation

Verdrengh M; Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, Guldhedsgatan 10A, S-41346 Göteborg, Sweden.

Bone ; 46(3): 752-8, 2010 Mar.

Article in En | MEDLINE | ID: mdl-19879986

Subject(s)

Arthritis, Experimental/drug therapy; Bone Resorption/prevention & control; Drug Delivery Systems/methods; RANK Ligand/administration & dosage; Staphylococcal Infections/drug therapy; Staphylococcus aureus; Animals; Anti-Bacterial Agents/therapeutic use; Arthritis, Experimental/microbiology; Bone Resorption/microbiology; Cell Line; Female; Humans; Mice; Mice, Inbred NZB; Osteoprotegerin/therapeutic use; RANK Ligand/antagonists & inhibitors; Signal Transduction/drug effects; Staphylococcal Infections/microbiology; Staphylococcus aureus/drug effects

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Arthritis, Experimental / Staphylococcal Infections / Staphylococcus aureus / Bone Resorption / Drug Delivery Systems / RANK Ligand Type of study: Prognostic_studies Language: En Journal: Bone Year: 2010 Type: Article Affiliation country: Sweden

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google